Phaseline

Companies › TYK Medicines

TYK Medicines: clinical trials, targets and expected readouts

2 active drug programs in 4 registered trials: 2 Phase 1, 1 Phase 3, 1 Phase 2; Oncology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TY-9591
EGFR inhibitor
–Phase 3NSCLCDec 2027
TYK-00540–Phase 1HR-positive, HER2-negative Advanced Breast Cancer; Locally Advanced or Metastatic Solid TumorsNov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06950086TYK-00540Phase 1HR-positive, HER2-negative Advanced Breast CancerOncologyNov 2026
NCT06246071TYK-00540Phase 1Locally Advanced or Metastatic Solid TumorsOncologyDec 2026
NCT05382728TY-9591Phase 3NSCLCOncologyDec 2027
NCT05948813TY-9591Phase 2NSCLCOncologyMar 2030

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Clarity Pharmaceuticals Impact Therapeutics TransThera Sciences (Nanjing) InxMed (Shanghai) Advenchen Laboratories

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.